Back to Newsroom

SUCAMPO AND HARBIN GLORIA PHARMACEUTICALS ENTER INTO LICENSING AGREEMENT FOR AMITIZA(R) (LUBIPROSTONE) IN CHINA

BETHESDA, Md., May 11, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that it entered into an exclusive license, development, commercialization and supply agreement with Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria), for AMITIZA® (lubiprostone) in the People’s Republic of China. Through this agreement, Sucampo has granted Gloria the rights to develop and commercialize AMITIZA in China, subject to regulatory approval of the product by the China Food and Drug Administration (CFDA).

Click here to read more